JamesRichardBerensonMD

PubMed

• 35 citations
  Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
  Yucai Wang, Fang Yang, Yan Shen, Wenwen Zhang, J. Wang
  Journal of the National Cancer Institute. 2016-03-01
• 49 citations
  Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
  James R. Berenson, Ori Yellin, Ralph V. Boccia, Marshall S. Flam, Siu Fun Wong
  Clinical Cancer Research. 2008-10-01
• 236 citations
  Interleukin-6 inhibits apoptosis of malignant plasma cells.
  Alan Lichtenstein, Yiping Tu, Catherine Fady, Robert Vescio, James R. Berenson
  Cellular Immunology. 1995-05-01

Abstracts/Posters

• Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Po...
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM). 
  2019 ASCO Annual Meeting - 6/1/2019
• A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 T... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all

Other

• Treatment of hypercalcemia 
  Berenson JR, Shane E
  http://www.uptodate.com/contents/treatment-of-hypercalcemia
  UpToDate, Wolters Kluwer Health - 2012-09-12
• The use of bisphosphonates in patients with multiple myeloma 
  Berenson JR
  http://www.uptodate.com/contents/the-use-of-bisphosphonates-in-patients-with-multiple-myeloma
  UpToDate, Wolters Kluwer Health - 2012-06-29
• Risks of therapy with bone modifying agents in patients with advanced malignancy 
  Berenson JR, Stopeck AT
  http://www.uptodate.com/contents/risks-of-therapy-with-bone-modifying-agents-in-patients-with-advanc
  UpToDate, Wolters Kluwer Health - 2013-01-22